home
portfolio
approach
team
careers
news
contact
investor portal
home
portfolio
approach
team
careers
news
contact
investor portal
Nextech Invest
A Novel Exosite Inhibitor that Selectively Reprograms TBK1-STING Pathway for Autoimmune Diseases
A Novel Exosite Inhibitor that Selectively Reprograms TBK1-STING Pathway for Autoimmune Diseases
Post navigation
Previous Post
Previous
Circle Pharma files first Investigational New Drug application for first-in-class oral cyclin A/B RxL inhibitor for treatment of advanced solid tumors
Next Post
Next
Tyra Biosciences Announces Preclinical Proof-of-Concept Results with TYRA-300 in Hypochondroplasia (HCH)